Office of Technology Transfer

The Office of Technology Transfer (OTT), in support of the University's mission to encourage innovation and disseminate knowledge, serves the University and the public by licensing innovations developed by faculty, students, and staff. Our services include evaluating, patenting, and licensing intellectual property.

Innovators from UM can use this site to learn why and how to protect their ideas, how to share their ideas with others, and when and how to start a company.

Companies can find out about technologies or research tools (cell lines, transgenic animals, etc.) available for licensing or learn about exciting UM startups looking for investment.

News and Events

Event flyer - Click for larger imageNanofluidics & Nanoparticles for Medical Application
Innovation at the intersection of medicine and engineering
UM Ventures presents an interactive seminar by Don L. DeVoe, PhD, from the Mechanical Engineering Department, University of Maryland College Park

Thursday, April 24, 2014, 5:30 PM
UM BioPark, 801 W. Baltimore Street
click for larger image

University of MD, Baltimore and Hopkins Faculty Researchers Win 2014 BioMaryland Life Prizes

LIFE Prize winner 2014    
Eduardo Davila, PhD of the Department of Microbiology and Immunology, University of Maryland School of Medicine, won an award for his T-cell based universal immunotherapy platform to fight cancer. Press Release (PDF) (2/19/14)

Photo (L to R): 
Dominick Murray, Secretary, Maryland Department of Business and Economic Development; Eduardo Davila, PhD, Associate Professor; Judy Britz, PhD, Executive Director, BioMaryland Center

   

SOP Researcher’s Entrepreneurism Recognized with Phase I Innovation Grant
Bruce Yu, PhD, associate professor in the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has received a $100,000 grant from the Maryland Innovation Initiative for investigation of novel, inexpensive method to detect protein aggregation in biopharmaceutical drugs. Read the SOP News Article (2/3/14)

UMB Licensee Countervail Corporation Receives Additional $5.4 Million from BARDA for Continued Development of Medical Countermeasure to Nerve Agents
Countervail Corporation announced on November 8 that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has exercised a contract option for an additional $5.4 million for the further development of galantamine hydrobromide, under the trade name AverTox(tm), as a medical countermeasure to the toxic effects of organophosphorus based nerve agents. BARDA exercised the option following an inter-agency In Process Review of the performance milestones completed by the company during the first phase of the contract. - Read the press release (11/12/13)

Researcher Patents Cancer Treatment - SOD News article (10/21/13)
Treatment method utilizes a combination of two natural compounds.

Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases - Gliknik press release (9/30/13)

Why Brain Surgeons Want Help From A Maggot-Like Robot
University of Maryland collaborators develop the Minimally Invasive Neurosurgical Intracranial Robot (MINIR) - Read more at NPR.org (9/27/13)

Initiation of Phase 3 clinical trial for UMB’s cholera vaccine - PaxVax press release (9/6/13)
The trial is being conducted at three locations, including UMB. The company has achieved FDA Fast Track designation for the vaccine.

MedImmune and University of Maryland, Baltimore Announce Five-year, $6 Million Research Collaboration to Drive Science Innovation in Maryland
Collaboration to drive novel bioscience research - MedImmune Press Release (9/25/13)

UMB's Partnership with Rexahn Pharmaceuticals - Exclusive license to Rexahn for development of cancer drug delivery platform co-developed by researchers at UMB's School of Pharmacy (7/17/13)
Press Release (PDF):  Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform: Maximizes efficacy and minimizes toxicity of currently marketed anti-cancer drugs RX-21101 identified as first development candidate from platform

Analytical Informatics, Inc. CEO Chris Meenan Featured on BioBuzz (Part Two) - UM Ventures News (9/9/13)

New opioid pain drug decreases tolerance, side effects - Fierce Research Biotech (8/29/13)
UMB Pharmacy Researchers Develop Promising Chronic Pain Drug
- UMB News Article (8/28/13)
University of Maryland Pharmacy Researchers Develop Promising Chronic Pain Drug - BioSpace Article (8/28/13)
Learn more about this technology
Link to the ACS abstract

Univ. of Maryland, Baltimore's licensing deals fuel local life sciences community - R&D Magazine (8/6/13)

Maryland Industrial Partnerships funds UMB Investigators
UMD Program Awards $3.8 Million to 17 University, Maryland Company Teams to Develop Technology Products - Wall Street Journal (7/16/13)
University of Maryland tech program awards $3.8M to researchers - Baltimore Business Journal (7/16/13)

Gammapod System Developed at the University of Maryland School of Medicine Targets Early-Stage Breast Cancer - SOM News Article (7/12/13)

UM Ventures Announces Collaboration Between UM School Of Medicine's Dr. Frank Robb and Fina Biosolutions - Wall Street Journal (7/11/13) Yahoo Finance (7/11/13)

UM Ventures and SilcsBio, LLC Announce Licensing Agreement - read the press release (6/6/13) (PDF)

UM Ventures Congratulates Tokai Pharma on Recent Fundraising Success
Tokai’s lead drug candidate, galeterone (TOK-001), is currently in Phase 2 clinical trials as a new therapy against prostate cancer. Galeterone was discovered by a UM Baltimore research team led by Professor  Angela Brodie, PhD, and Professor Vincent Njar, PhD.

Read more at:
http://tokaipharma.com/pdfs/Tokai-Series-E-Financing-PR-FINAL-51513.pdf (PDF)
http://www.umgcc.org/news/angela-h-brodie.htm
http://medschool.umaryland.edu/cbt/

2013 Entrepreneur of the Year - Scott Strome

Dr. Strome's profile

OTT News Archive